Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Sionna Therapeutics, Inc.
Market Cap
$214.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
Gross Margin
64.24%
TTM Avg
63.06%
3Y Avg
61.57%
5Y Avg
61.22%
Market Cap
$215.07M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$216.91M
Gross Margin
85.91%
TTM Avg
92.95%
3Y Avg
46.48%
5Y Avg
30.98%
Market Cap
$210.98M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$218.30M
Gross Margin
94.68%
TTM Avg
99.69%
3Y Avg
74.84%
5Y Avg
66.56%
Market Cap
$210.41M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | 0.00% | 0.00% | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 64.24% | 63.06% | 61.57% | 61.22% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 87.24% | 79.57% | 65.64% | 63.99% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 85.91% | 92.95% | 46.48% | 30.98% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 94.68% | 99.69% | 74.84% | 66.56% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 83.89% | 91.94% | 70.97% | 47.31% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 86.89% | 79.42% | 84.96% | 87.58% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | 71.79% | 68.33% | 60.69% | 55.54% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
